NVO

Novo Nordisk AS

124.28 USD
+3.35 (+2.77%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Novo Nordisk AS stock is up 17.95% since 30 days ago. The next earnings date is May 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.79% of the previous 42 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Feb 16:58 17 Jan, 2025 155.00 CALL 120 1158
22 Feb 17:04 19 Apr, 2024 135.00 CALL 226 427
22 Feb 17:04 21 Jun, 2024 125.00 CALL 30 1447
22 Feb 17:13 21 Jun, 2024 80.00 CALL 10 91
22 Feb 17:16 23 Feb, 2024 115.00 CALL 55 143
22 Feb 17:22 21 Jun, 2024 80.00 CALL 10 91
22 Feb 17:26 16 Jan, 2026 115.00 CALL 10 287
22 Feb 17:36 21 Jun, 2024 80.00 CALL 10 91
22 Feb 18:01 01 Mar, 2024 117.00 CALL 35 405
22 Feb 18:01 01 Mar, 2024 117.00 CALL 35 405

About Novo Nordisk AS

Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

  • Cantor Fitzgerald
    Tue Feb 20, 12:42
    buy
    confirm
  • Cantor Fitzgerald
    Thu Feb 15, 09:18
    buy
    confirm
  • Cantor Fitzgerald
    Wed Feb 14, 11:32
    buy
    confirm
  • Cantor Fitzgerald
    Thu Feb 1, 12:04
    buy
    confirm